Company intelligence / Profile preview

Kimera Labs

Miramar, Florida, United Stateskimeralabs.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Received FDA IND clearance for Phase I/IIa human study of MSC exosomes in May 2023. Currently conducting a 160-patient clinical trial for treating inflammation associated with COVID-19.

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Mesenchymal stem cell (MSC)-derived exosomes
Industry: Biotech

Drug pipeline

1 asset

placental mesenchymal stem cell-derived exosomes

Unknown

Beyond the preview

Go deeper on Kimera Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kimera Labs.

Explore the full profile